We are live on ! Find out more
DGM

Darwin Global Management Portfolio holdings

AUM $3.77B
1-Year Est. Return 307.72%
This Fund
S&P 500
This Quarter Est. Return
+157.09%
1 Year Est. Return
+307.72%
3 Year Est. Return
+2,873.14%
5 Year Est. Return
+48,315.58%
10 Year Est. Return
–
AUM
$66.4M
AUM Growth
-$122M
Cap. Flow
-$141M
Cap. Flow %
-213.05%
Top 10 Hldgs %
100%
Holding
3
New
2
Increased
–
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
VTYX
Ventyx Biosciences
VTYX
+$31M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$15.7M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$188M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTYX
1
DELISTED
Ventyx Biosciences
VTYX
$48.9M 73.66%
+1,401,123
New +$31M
KRTX
2
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$17.5M 26.34%
+77,768
New +$15.7M
AZN icon
3
AstraZeneca
AZN
$262B
– –
-1,424,555
Closed -$188M

Similar funds

VVP
Vulcan Value Partners Birmingham, Alabama $3.77B AUM 9.63% 1-Year Est. Return
ABC
Associated Banc-Corp Green Bay, Wisconsin $3.78B AUM 21.74% 1-Year Est. Return
SCA
Snowden Capital Advisors New York $3.76B AUM 23.4% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
VA
VestGen Advisors Inverness, Illinois $3.76B AUM 26.04% 1-Year Est. Return
GCC
Guardian Capital (Canada) Toronto, Ontario, Canada $3.78B AUM 33.04% 1-Year Est. Return
SB
SIG Brokerage New York $3.79B AUM 44.46% 1-Year Est. Return

Darwin Global Management's Q3 2022 Portfolio in Review

As of Q3 2022, Darwin Global Management held 3 positions worth $66.4M, down 65% from $188M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Darwin Global Management withdrew a net $141M in Q3 2022, closing 1 position. Its most notable exit was AstraZeneca, an estimated $188M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Darwin Global Management opened a new position in Ventyx Biosciences worth $48.9M.

  • Darwin Global Management's largest Q3 2022 buy was Ventyx Biosciences: 1,401,123 shares worth $48.9M.
  • Darwin Global Management fully exited AstraZeneca in Q3 2022, selling an estimated $188M.
  • Darwin Global Management's ten largest holdings make up 100% of its $66.4M portfolio in Q3 2022.
  • Darwin Global Management opened 2 new positions and closed 1 in Q3 2022.
  • Darwin Global Management's portfolio value fell 65% quarter-over-quarter to $66.4M.

Based on Darwin Global Management's 13F filing for Q3 2022, filed 14 Nov 2022.